102 related articles for article (PubMed ID: 10523677)
21. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
22. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
23. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
24. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
25. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
[TBL] [Abstract][Full Text] [Related]
26. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer.
Capietto AH; Martinet L; Fournié JJ
J Immunol; 2011 Jul; 187(2):1031-8. PubMed ID: 21670311
[TBL] [Abstract][Full Text] [Related]
27. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
28. An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine.
Bird RC; Deinnocentes P; Church Bird AE; van Ginkel FW; Lindquist J; Smith BF
Cancer Immunol Immunother; 2011 Jan; 60(1):87-97. PubMed ID: 21069323
[TBL] [Abstract][Full Text] [Related]
29. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.
Ryan MH; Bristol JA; McDuffie E; Abrams SI
J Immunol; 2001 Oct; 167(8):4286-92. PubMed ID: 11591751
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
31. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
32. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice.
Schüler T; Qin Z; Ibe S; Noben-Trauth N; Blankenstein T
J Exp Med; 1999 Mar; 189(5):803-10. PubMed ID: 10049944
[TBL] [Abstract][Full Text] [Related]
33. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
[TBL] [Abstract][Full Text] [Related]
34. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction.
Abe J; Wakimoto H; Tsunoda R; Okabe S; Yoshida Y; Aoyagi M; Hirakawa K; Hamada H
Biochem Biophys Res Commun; 1996 Jan; 218(1):164-70. PubMed ID: 8573124
[TBL] [Abstract][Full Text] [Related]
35. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Jeglum KA; Santoli D
Clin Cancer Res; 1999 Jul; 5(7):1868-75. PubMed ID: 10430094
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
38. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
[TBL] [Abstract][Full Text] [Related]
39. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
[TBL] [Abstract][Full Text] [Related]
40. In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas.
Shibata MA; Ito Y; Morimoto J; Kusakabe K; Yoshinaka R; Otsuki Y
J Gene Med; 2006 Mar; 8(3):335-52. PubMed ID: 16345101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
